7 m-thick sections of formalin-fixed, paraffinembedded blocks of temporal lobe (including the parahippocampal gyrus (Brodmann area 36), the inferior (area 20), middle (area 21) and superior temporal (area 22) gyri and the hippocampus) were immunostained for clusterin. Dewaxed and hydrated sections were immersed in methanol containing 3% hydrogen peroxide (30 min), boiled in sodium citrate buffer (pH 6), blocked in Vectastain blocking
serum (20 min; Vectastain Universal Elite ABC kit, Vector Laboratories, Peterborough, UK) and incubated with anti-clusterin antibody (1 : 1500, overnight; Santa Cruz Biotechnology, Heidelberg, Germany). This was followed by incubation with Vectastain biotinylated universal secondary antibody (20 min; Vector Laboratories), avidin-biotin horseradish peroxidase complex (20 min; VectaElite ABC; Vector Laboratories) and 3,3 -diaminobenzidine (10 min; DAB, Vector Laboratories). All incubations were at room temperature. Sections were counterstained with hematoxylin, dehydrated, cleared and mounted. Clusterin mRNA levels in the frontal and temporal cortex and thalamus of Alzheimer's disease (AD) and normal control brains were measured by real-time PCR. The fold change in CLU expression in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), neuron-specific enolase (NSE) and microtubule-associated protein (MAP)-2 was calculated using the 2 − Ct method [1] . These exponential data are presented as geometric mean and 95% confidence intervals. Significant changes in expression between AD and control groups were assessed using the Mann Whitney U test (p values). *Significant values.
Supplementary Neuron-specific enolase (NSE), microtubule-associated protein (MAP)-2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels in the frontal and temporal cortex and thalamus of Alzheimer's disease (AD) and normal control brains were measured by real-time PCR.
The fold change in expression of NSE and MAP-2 in relation to GAPDH was calculated using the 2 − Ct method [1] . # Changes in GAPDH expression were calculated using a slight variation of the method (2 − C t ) [1] . These exponential data are presented as geometric mean and 95% confidence intervals. Significant changes in expression between AD and control groups were assessed using the Mann Whitney U test (p values). *Significant values.
Supplementary Changes in clusterin mRNA levels with increasing Braak stage were assessed by Spearman's correlation. CLU expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), neuron-specific enolase (NSE) and microtubule-associated protein (MAP)-2. Cases were grouped into Braak stage 0-2, 3-4 and 5-6. *Significant values.
